Timothy L. CannonMD
Dr. Timothy Cannon is a medical oncologist and clinical director of the Inova Schar Institute Molecular Tumor Board (MTB). He specializes in gastrointestinal malignancies and is an assistant professor at Virginia Commonwealth University. He has been the moderator of the MTB since it began in March of 2016, which matches patients with targeted therapies based on molecular diagnostics. He is the site principal investigator for the Targeted Agent and Profiling Utilization Registry (TAPUR) study, as well as many other clinical trials in immunotherapy.
Dr. Cannon received his M.D. from Rutgers Medical School and completed his residency at George Washington University Medical Center Internal Medicine. He completed a fellowship in hematology/oncology at New York University, where he was the chief fellow.